Fresenius acquires remaining 45% of mAbxience from Insud Pharma
AI Summary- Fresenius acquired Insud Pharma’s remaining stake in mAbxience.
- The transaction covered 45% after Fresenius bought 55% in August 2022.
- mAbxience will continue existing customer support and worldwide biosimilar supply commitments.